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Abstract
Background
Plasmodium vivax malaria (Pv-malaria) is still considered a neglected disease despite an
alarming number of individuals being infected annually. Malaria pathogenesis occurs with
the onset of the vector-parasite-host interaction through the binding of pathogen-associated
molecular patterns (PAMPs) and receptors of innate immunity, such as toll-like receptors
(TLRs). The triggering of the signaling cascade produces an elevated inflammatory
response. Genetic polymorphisms in TLRs are involved in susceptibility or resistance to
infection, and the identification of genes involved with Pv-malaria response is important to
elucidate the pathogenesis of the disease and may contribute to the formulation of control
and elimination tools.
Methodology/Principal findings
A retrospective case-control study was conducted in an intense transmission area of Pv-
malaria in the state of Amazonas, Brazil. Genetic polymorphisms (SNPs) in different TLRs,
TIRAP, and CD14 were genotyped by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis in 325 patients infected with P. vivax and 274 healthy
individuals without malaria history in the prior 12 months from the same endemic area. Para-
site load was determined by qPCR. Simple and multiple logistic/linear regressions were per-
formed to investigate association between the polymorphisms and the occurrence of Pv-
malaria and parasitemia. The C/T (TLR5 R392StopCodon) and T/T (TLR9 -1486C/T)
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genotypes appear to be risk factors for infection by P. vivax (TLR5: C/C vs. C/T [OR: 2.116,
95% CI: 1.054–4.452, p = 0.031]; TLR9: C/C vs. T/T [OR: 1.919, 95% CI: 1.159–3.177, p =
0.010]; respectively). Fever (COEF = 7599.46, 95% CI = 3063.80–12135.12, p = 0.001) and
the C/C genotype of TLR9 -1237C/T (COEF = 17006.63, 95% CI = 3472.83–30540.44, p =
0.014) were independently associated with increased parasitemia in patients with Pv-malaria.
Conclusions
Variants of TLRs may predispose individuals to infection by P. vivax. The TLR5 R392Stop-
Codon and TLR9 -1486C/T variants are associated with susceptibility to Pv-malaria. Fur-
thermore, the TLR9 variant -1237C/C correlates with high parasitemia.
Introduction
Approximately 214 million cases of malaria were diagnosed in 2015, with 438,000 deaths [1].
In Brazil, 140,000 cases were reported, representing 41.7% of cases in the Americas [2,3]. The
Amazon region contributes nearly 99.9% of the malaria notifications, and Plasmodium vivax is
responsible for 83.7% of cases [4,5].
Malaria results in a wide spectrum of clinical manifestations that occur during the vector-
parasite-host interaction, and the first asexual reproduction process occurs in the liver [6,7].
Febrile episodes of malaria start after the interaction between the toxins that are produced by
the schizont and released during the rupture of red blood cells and the phagocytic cells of the
innate immune system [8]. These toxins, also called pathogen associated molecular patterns
(PAMPs) are mainly recognized by toll-like receptors (TLRs) [9]. The Plasmodium PAMPs such
as the glycosylphosphatidylinositol anchors (GPI), hemozoin linked to DNA are recognized by
TLR-1/TLR-2, TLR-4, TLR-2/TLR-6, and TLR-9, respectively, producing an intense inflamma-
tory response and activating dendritic cells, monocyte subtypes, and macrophages [10–16].
The inflammatory response resulting from the pathogenesis of the disease is closely related
to the parasite load and the genetic background of the host [17]. Inflammation and cytokine
production were reported to be higher in P. vivax infection than that in other species such as
Plasmodium falciparum [18–20]. Deletion of TLRs and co-stimulatory molecules in murine
models showed decreased production of proinflammatory cytokines and increased susceptibil-
ity to infection by different species of Plasmodium and other protozoans [11,21–23].
Genetic polymorphisms in TLRs are involved in cytokine activation pathways and may play
a role in resistance or susceptibility to Plasmodium infection. The variant TLR1 I602S was asso-
ciated with the development of symptomatic malaria and high parasitemia in P. falciparum
malaria (Pf-malaria) [24,25]. Single nucleotide polymorphisms (SNPs) in TLR4 (A299G and
T399I) were shown to be associated with the onset of clinical manifestations of severe Pf-
malaria in African children and pregnant women, and in adults with non-severe symptomatic
malaria [26–28]. Individuals with the SNP R392StopCodon (TLR5) are unable to induce the
intracellular signaling cascade in bacterial diseases, producing lower concentrations of inflam-
matory cytokines such as IL-6 and TNF-α [29,30]. Cytokines are important for parasite load
control and Plasmodium clearance in humans [15,31]
The TLR6 S249P polymorphism may be a risk factor for the development of malaria [24].
Allelic variants in the promoter region of TLR9 -1237C/T and -1486C/T are associated with
parasitemia in Pf-infected individuals and placental malaria [24,27]. The SNP of TIR domain-
containing adaptor protein (TIRAP) S180L appears to confer protection against malaria,
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tuberculosis, and bacterial diseases [32]. CD14–159 is associated with the incidence and mor-
tality of septic shock [33,34].
P. vivax has several PAMPs that are recognized by TLRs, and studies have shown that poly-
morphisms in the TLR genes may be associated with Pf-malaria. In this study, SNPs in the
TLRs, TIRAP, and CD14 genes were investigated in P. vivax infected individuals from the
Amazon region of Brazil. Association of the polymorphisms TLR5 R392StopCodon and TLR9
-1486C/Twith Pv-malaria and the C/C genotype of the SNP TLR9 -1237C/Twith increased
parasitemia was observed.
Materials and methods
Study area and sampling
The study was conducted with biological samples collected from individuals of two areas of the
state of Amazonas, based on the low intra-regional migration of its inhabitants and similar
profiles of malaria transmission. The regions chosen were followed in two cohort studies, enti-
tled "The epidemiology of malaria in the municipality of Careiro", and "The comparative epi-
demiology of P. falciparum and P. vivax transmission in Papua New Guinea, Thailand and
Brazil", carried out in rural and peri-urban areas of the cities of Careiro and Manaus from
2008 to 2011 and 2013 to 2014, respectively.
The Careiro municipality, which is 110 km from the Amazonas state capital Manaus, has
access to a federal highway (BR-319), and has an estimated population of 30,000. Most inhabitants
live in rural areas and are supported by federal programs that encourage the practice of agricul-
ture. The Panelão and Sı´tio Castanho communities comprise an estimated population of 1,200,
and were chosen for the study due to the observation of intense transmission of Pv-malaria [35].
The communities Brasileirinho, Ipiranga, and Puraquequara, located in the peri-urban area
east of Manaus, had an estimated population of 2,500 at the end of 2012, according to a census
conducted by the FMT-HVD team shortly before our sample collection. There is uncontrolled
deforestation in these areas. The economy is mainly based on agricultural and extraction activ-
ities, and is at high risk of Pv-infection [36].
A retrospective case-control study was conducted from the two cohorts. A total of 325
patients with Pv-malaria diagnosed by thick blood smear examination [37] and confirmed by
qPCR [38] were included in the study, along with 274 healthy individuals with no malaria his-
tory in the prior 12 months and confirmed negative by qPCR for Plasmodium spp. during the
cohort studies (Fig 1). All study participants were from the same endemic area, sharing similar
environments and risk of exposure to the parasite.
Ethics statement
The studies were approved by the Comitê de E´tica em Pesquisa da Fundac¸ão de Medicina
Tropical Dr. Heitor Vieira Dourado (CEP/FMT-HVD process #51536/2012), and by the
Comissão Nacional de E´tica em Pesquisa (CONEP) linked to the Conselho Nacional de Sau´de
(CONEP process #15197/2008, #349211/2013). All participants read and signed the written
informed consent form. Malaria cases detected in longitudinal studies were treated in accor-
dance with the recommendations of the Brazilian Ministry of Health [39].
Genomic DNA extraction
Samples of 300 μL of blood were collected via finger puncture from each participant for geno-
mic DNA purification. The QIAmp DNA kit (QIAGEN, Chatsworth, CA, USA) was used for
the Careiro study, and the FavorPrepTM 96-well Genomic DNA Kit (Favorgen, Ping-Tung,
TLRs polymorphisms and Plasmodium vivax malaria
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Taiwan) was used for the Manaus study. DNA samples were quantified with a NanoDrop
2000c (Thermo Fisher Scientific, Waltham, MA, USA) to evaluate the concentration, and
purity of nucleic acids.
Quantification of P. vivax DNA by qPCR assay
Parasitemia of Pv-malaria was determined by amplifying the 18S rRNA gene using the 7500
Fast qPCR System (Applied Biosystems, Foster, CA, USA) as described previously [40,41], and
is expressed as number of copies/μL. The primers/probes, qPCR cycling conditions, qPCR effi-
ciency and detection limit are shown in S1 Table. Parasitemia was obtained for only 208 Pv-
malaria patients (Fig 1).
Polymorphism genotyping
The following polymorphisms, TLR1 I602S, (rs5743618), TLR4 A299G (rs4986790), TLR4
T399I (rs4986791), TLR5 R392StopCodon (rs5744105), TLR6 S249P (rs5743810), TLR9 -1237C/
Fig 1. Study and data analysis flow chart. We included 599 eligible participants from two cohort studies conducted in Amazonas. Of these, 274 healthy
individuals without malaria history in the prior 12 months were included in the “Healthy Group” and 325 patients diagnosed with Pv-malaria infection were
included in the “Pv-malaria Cases”. Parasitemia analysis was performed for 208 patients.
https://doi.org/10.1371/journal.pone.0183840.g001
TLRs polymorphisms and Plasmodium vivax malaria
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T (rs187084), TLR9 -1486C/T (rs5743836), TIRAP S180L (rs8177374), and CD14–159
(rs2569191) were investigated. Polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) analysis was used for allelic discrimination as described previously [24,42,
43]. Briefly, the PCR reaction for each SNP consisted of 1 μL genomic DNA (~ 20ng) added to
24 μL amplification mix containing 0.2 μL (2 U) Platinum™ Taq polymerase (Thermo Fisher
Scientific), 2.5 μL 10x buffer (100 mmol/L Tris-HCl [pH 8.3] and 500 mmol/L KCl), 1 μL
MgCl2 (1.5 mmol/L), 1 μL dNTPs (40 mmol/L), 0.5 μL each of forward and reverse primer (0.25
pmol/L) and 18.3 μL ultrapure dH2O. A total of 10 μL of PCR product was digested with 5 U of
respective restriction endonuclease (New England Biolabs, Ipswich, MA, USA) in enzyme
buffer according to the manufacturer’s instructions. The primers, PCR cycling conditions, and
restriction endonucleases are shown in S2 Table. The fragments generated by PCR-RFLP were
separated by electrophoresis in either a 2% or 4% agarose gel stained with GelRed™ Nucleic
Acid Gel Stain (Biotium, Hayward, CA, USA), and visualized with the UV light Gel Doc™ XR
+ System (Bio-Rad Corporation, Hercules, CA, USA) with a photo documentation system.
Statistical and data analysis
Comparison between groups was performed with the chi-squared (χ2) or Fisher’s exact test
with 95% confidence interval [CI]. The Hardy-Weinberg equilibrium (HWE) was determined
by comparing the frequency of the observed and expected number of genotypes. Simple and
multiple logistic regressions were performed to investigate association between the polymor-
phisms and the occurrence and recurrence of Pv-malaria and parasitemia. For both regression
analyses, the variables age, gender, fever, and hemoglobin levels were included as confounders.
A backward stepwise technique was applied. Variables with p-values less than or equal to 0.2
in the simple linear regression were selected for the multivariate model analysis. The final
model considered all variables that were statistically significant (p<0.05). The analysis of hap-
lotypes and linkage disequilibrium (LD) was carried out by Haploview software (v4.2). Tests
for Hardy-Weinberg equilibrium were performed by an online application (https://ihg.gsf.de/
cgi-bin/hw/hwa1.pl). Regression models were performed by Stata software (v13).
Results
Baseline characteristics of the study population
Baseline characteristics of the study population are shown in Table 1. The median age of the
healthy control and Pv-malaria cases were 39 and 37 years, respectively (p = 0.744). In both
Table 1. Clinical and demographic characteristics of the study population.
Variables Healthy Group Pv-malaria Cases
(n = 274) (n = 325)
Age (years, median [IQR]) 39 [20–57] 37 [19–53]
Gender (male/female) 151/123 200/125
Parasitemia (number of copies/μL, median [IQR]) - 188 [25.5–2,881.5]
Number of infections (median [IQR]) - 2 [0–8]
First infection (yes/no) - 89/236
Fever (yes/no) - 177/148
Headache (yes/no) - 102/223
Chills (yes/no) - 95/230
Myalgia (yes/no) - 90/235
Sweating (yes/no) - 52/273
Hemoglobin (g/dL, median [IQR]) - 13.7 [12.6–14.6]
https://doi.org/10.1371/journal.pone.0183840.t001
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groups, male subjects were predominant (55% and 62%). The average parasite load was 188
copies/uL. A median of 2 malarial episodes was reported by the patients. Approximately 27%
of the Pv-malaria cases were primary infections. Patients reported fever (54%), headache
(31%), chills (29%), myalgia (28%) and sweating (16%). The median hemoglobin level was
13.7 g/dL.
Association of the genotypes and alleles of polymorphisms in TLR5
R392StopCodon and TLR9 -1486C/T with P. vivax malaria
Of all the SNPs studied, only TLR9 -1486C/T slightly deviated from the HWE in Pv-malaria cases
(p = 0.006). TIRAP S180L was null in the population studied. The genotypic and allelic frequen-
cies for all the SNPs are shown in Table 2. The genotype distributions for TLR5 R392StopCodon
and TLR9 -1486C/Twere significantly different between the groups (p = 0.03 and p = 0.01,
respectively). The genotypes C/T (TLR5 R392StopCodon) and T/T (TLR9 -1486C/T) appear to be
risk factors for Pv-infection (TLR5: C/C vs. C/T OR = 2.1 [95% CI: 1.1–4.5, p = 0.031]; TLR9:
C/C vs. T/T OR = 1.9, [95% CI: 1.2–3.2, p = 0.01]; TLR9: C/C vs. C/T+T/T OR = 1.6, [95% CI:
1.1–2.5, p = 0.024]). Similar trends were observed at the allele levels for both SNPs. Carriers of
the T allele were at higher risk for developing Pv-malaria (TLR5 OR = 2.1, [95% CI: 1.0–4.3,
p = 0.034]; TLR9 OR = 1.3, [95% CI: 1.0–1.7, p = 0.02]).
The TLR9 -1237C/C genotype is associated with increased parasitemia
in Pv-malaria
Table 3 summarizes the univariable and multivariable linear regression analyses for parasite-
mia association with the different variables. Fever (COEF = 7599.46, 95% CI = 3063.80–
12135.12, p = 0.001) and the C/C genotype of TLR9 -1237C/T (COEF = 17006.63, 95%
CI = 3472.83–30540.44, p = 0.014) were independently associated with increased parasitemia.
Linkage disequilibrium of the TLR polymorphisms
Linkage disequilibrium (LD) between polymorphisms in receptors TLR1 and TLR6 (I602S vs.
S249P), TLR4 (A299G vs. T399I), and TLR9 (-1237C/T vs. -1486C/T) was very low, as calculated
by Haploview 4.2 software. The R2 and D’ of the LD were 0.38 and 0.83 for TLR1 and TLR6,
0.18 and 0.44 for TLR4, 0.006 and 0.20 for TLR9.
Discussion
Pv-malaria is still considered a neglected disease despite various efforts directed to its control
and elimination [44–46]. P. vivax presents biological complexity due to the interplay between
environmental factors, parasite load, and the immunological status and genetic background of
the human host [17,47]. The hypnozoite stage in the liver can cause clinical episodes of relapse
with lower parasite load. These are often associated with mild or asymptomatic clinical display
and contribute to the transmission of the disease [48,49]. The molecular mechanisms influenc-
ing these characteristics remain poorly understood. Knowledge of the host genetic factors in
malaria may contribute to the elucidation of the molecular mechanisms involved in the devel-
opment of the disease, as not all individuals exposed to the parasites develop symptoms. The
identification of genes involved in susceptibility or resistance to infection by P. vivax is impor-
tant to understand the pathogenesis of the disease and may contribute to the designing of con-
trol and elimination tools, as well as the development of an effective vaccine.
Innate immunity plays a key role in infectious processes. The discovery of pattern recogni-
tion receptors (PRRs) such as TLRs, Nod-like receptors (NLRs), RIG-I-like receptors (RLRs),
TLRs polymorphisms and Plasmodium vivax malaria
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Table 2. Genotype and allele frequencies of the TLRs and CD14 polymorphisms in patients with Pv-malaria and healthy controls.
Polymorphism, Genotype or Allele Healthy Group Pv-malaria Cases OR (IC 95%) p-value
(n = 274) (n = 325)
TLR1 I602S (rs5743618)
T/T 153 (56%) 188 (58%) 0.9 (0.7–1.3) 0.621 T/T vs. T/G+G/G
T/G 107 (39%) 118 (36%) 0.9 (0.6–1.3) 0.530 T/T vs. T/G
G/G 14 (5%) 19 (6%) 1.1 (0.5–2.3) 0.787 T/T vs. G/G
T 413 (75%) 494 (76%) 1.0
(0.8–1.3)
0.798
G 135 (25) 156 (24%)
TLR4 A299G (rs4986790)
A/A 260 (95%) 312 (96%) 0.8 (0.4–1.7) 0.514 A/A vs. A/G
A/G 14 (5%) 13 (4%)
G/G - -
A 534 (97%) 637 (98%) 1.3
(0.6–2.8)
0.519
G 14 (3%) 13 (2%)
TLR4 T399I (rs4986791)
C/C 261 (95%) 310 (95%) 1.0 (0.5–2.1) 0.940 C/C vs. C/T
C/T 13 (5%) 15 (5%)
T/T - -
C 535 (98%) 635 (95%) 1.0
(0.5–2.2)
0.941
T 13 (2%) 15 (5%)
TLR5 R392StopCodon (rs5744105)
C/C 263 (96%) 298 (92%) 2.1 (1.1–4.5) 0.031 CC vs. CT
C/T 11 (4%) 27 (8%)
T/T - -
C 537 (98%) 623 (96%) 2.1
(1.0–4.3)
0.034
T 11 (2%) 27 (4%)
TLR6 S249P (rs5743810)
C/C 4 (1%) 13 (4%) 1.0 (0.7–1.5) 0.889 C/C+C/T vs. T/T
C/T 73 (27%) 80 (25%) 0.3 (0.1–1.1) 0.057 C/C vs. C/T
T/T 197 (72%) 232 (71%) 0.4 (0.1–1.1) 0.068 C/C vs. T/T
C 81 15%) 106 (16%) 0.9
(0.7–1.2)
0.468
T 467 (85%) 544 (84%)
TLR9 -1237C/T (rs187084)
T/T 192 (70%) 222 (68%) 1.1 (0.8–1.5) 0.641 C/C vs. C/T+T/T
C/T 76 (28%) 93 (29%) 1.1 (0.7–1.5) 0.757 C/C vs. C/T
C/C 6 (2%) 10 (3%) 1.4 (0.5–4.0) 0.484 C/C vs. T/T
T 460 (84%) 537 (83%) 1.1
(0.8–1.5)
0.540
C 88 (16%) 113 (17%)
TLR9 -1486C/T (rs5743836)
C/C 56 (20%) 44 (14%) 1.9 (1.2–3.2) 0.010 C/C vs. T/T
C/T 153 (56%) 183 (56%) 1.5 (1.0–2.4) 0.065 C/C vs. C/T
T/T 65 (24%) 98 (30%) 1.6 (1.1–2.5) 0.024 C/C vs. C/T+T/T
C 265 (48%) 271 (42%) 1.3
(1.1–1.6)
0.020
T 283 (52%) 379 (58%)
CD14–159 (rs2569191)
C/C 91 (33%) 99 (31%) 1.2 (0.9–1.8) 0.244 C/C vs. C/T
C/T 118 (43%) 160 (49%) 1.2 (0.8–1.8) 0.313 C/C+C/T vs. T/T
T/T 65 (24%) 66 (20%) 1.3 (0.9–2.0) 0.173 C/T vs. T/T
(Continued )
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and scavenger receptors has contributed to the understanding of infectious disease [50,51].
TLRs are key mediators in the response to malaria, playing an important role in the bridge
between innate and adaptive immunity, mainly by activation of transcription factor NF-κB
and inducing production of proinflammatory cytokines [52]. SNPs in TLRs and adapter
molecules that influence the inflammatory process and proinflammatory cytokine production
may be associated with susceptibility to infections [34,53,54]. Changes in the production of
these cytokines may influence the control of parasitemia and clinical manifestations of the
disease, since a fine balance in the inflammatory process is essential for parasite clearance
[15,16,55,31]. The data presented in this study suggest an association of polymorphisms TLR5
and TLR9 with Pv-malaria. Furthermore, the SNP TLR9 -1237C/Twas associated with
increased parasitemia.
Allelic variants of TLR1 I602S and TLR6 S249P showed no association with Pv-malaria. An
association of polymorphisms in TLR1 and TLR6 with mild malaria in patients infected with
different Plasmodium species was recently demonstrated. Variants in TLR1 may predispose
patients with Pf-malaria complications and increased parasitemia [24,25]. In addition, SNPs
I602S (TLR1) and S249P (TLR6) were associated with severe malaria in Indian patients, show-
ing the genetic contribution of these variants to the onset of cerebral malaria [56]. TLR-1 and
-6 form heterodimers with TLR-2 and recognize the GPI anchor of the parasite. Mutations in
these receptors can impair recognition and subsequent elimination of Plasmodium [12,24].
SNPs in TLR4 were not associated with Pv-malaria in our study. These polymorphisms
have been associated with severe manifestations of malaria in children and mild symptoms in
pregnant African women infected with P. falciparum [26,27]. Furthermore, T399I and A299G
in TLR4 were associated with increased parasitemia in Indian patients with Pf-malaria, indicat-
ing that this receptor is important in inducing immune response to malaria [57]. In addition,
these SNPs appeared to modulate the susceptibility to severe anemia and malaria in Nigerian
children [58,59]. Moreover, there was no correlation between these polymorphisms and com-
plications of malaria in adult patients and in other parasitic diseases, such as chronic Chagas
disease [28,60,61], and this study corroborates this lack of association. The TLR4/CD14 com-
plex is responsible for cytokine production via NF-κB, and the SNP CD14–159 in the promoter
region has been associated with susceptibility to tuberculosis, and was shown to influence the
production of IFN-γ [62–64]. Our data does not show any association of this SNP with Pv-
malaria or parasitemia.
Flagellin (FliC), present in bacteria and parasites, is a ligand of TLR-5. Activation of TLR-5
leads to the production of proinflammatory cytokines such as IL-6 [65]. To our knowledge,
this is the first report of an association of the SNP R392StopCodon in TLR5 with susceptibility
to Pv-malaria. TLR-5 was shown to be a promising alternative to enhance the immunogenicity
of the proteins to specific P. vivax, such as the 19 kDa C-terminal fragment of merozoite sur-
face protein 1 (MSP119) after combination with Salmonella enterica serovar Typhimurium
FliC [66,67]. Thus, we suggest that individuals with this mutation may not react favorably to
this vaccine design. Alternative vaccines for carriers of this mutation must be sought.
The association of the -1486C/T variant present in the promoter region of TLR9 with
Pv-malaria in this study corroborated other observations of association of this SNP with
Table 2. (Continued)
Polymorphism, Genotype or Allele Healthy Group Pv-malaria Cases OR (IC 95%) p-value
(n = 274) (n = 325)
C 300 (55%) 358 (55%) 1.0
(0.8–1.3)
0.908
T 248 (45%) 292 (45%)
https://doi.org/10.1371/journal.pone.0183840.t002
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Table 3. Association of parasitemia with TLR and CD14 polymorphisms in Pv-malaria patients.
Variables Parasitemia
(number of copies / μL)
Crude COEFa
(IC 95%)
p-value Adjusted COEFb
(IC 95%)
p-value
Age -134.9
(-240.4 to -29.4)
0.012 -80.0
(-185.7 to 25.6)
0.137
Gender (Male) 1 - 1 -
Female -1305.8
(-6,131.9 to 3,520.1)
0.594 - -
Fever (No) 1 - 1 -
Yes 8630.2
(4,114.1 to 13,146.2)
<0.0001 7599.5
(3,063.8 to 12,135.1)
0.001
Hemoglobin -661.7
(-2,160.9 to 837.4)
0.385 - -
TLR1 602 (G/G) 1 - 1 -
(T/G) 1872.6
(-8,143.7 to 11,888.9)
0.713 - -
(T/T) 5111.41
(-4,702.3 to 14,925.1)
0.306 - -
TLR4 299 (A/A) 1 - 1 -
(A/G) -4766.5
(-17,680.3 to 8,147.3)
0.468 - -
TLR4 399 (C/C) 1 - 1 -
(C/T) -3050.6
(-14,503.7 to 8,402.4)
0.600 - -
TLR5 392 (C/C) 1 - 1 -
(C/T) 5609.1
(-3,372.2 to 14,590.5)
0.220 - -
TLR6 249 (C/C) 1 - 1 -
(C/T) 3510.9
(-8,571.6 to 15,593.3)
0.567 - -
(T/T) 5610.6
(-5,934.8 to 17,156.1)
0.339 - -
TLR9–1237 (T/T) 1 - 1 -
(C/T) 2006.9
(-3,259.7 to 7,273.4)
0.453 - -
(C/C) 21633.9
(7,922.5 to 35,345.3)
0.002 17006.6
(3,472.8 to 30,540.4)
0.014
TLR9–1486 (C/C) 1 - 1 -
(C/T) -155.6
(-7,297.8 to 6,986.6)
0.966 - -
(T/T) -3133.6
(-10,963.1 to 4,695.9)
0.431 - -
CD14–159 (C/C) 1 - 1 -
(C/T) -1374.1
(-6,668.6 to 3,920.4)
0.609 - -
(T/T) 2708.8
(-4,073.2 to 9,490.9)
0.432 - -
aUnivariable regression linear model.
bMultivariable regression linear model.
https://doi.org/10.1371/journal.pone.0183840.t003
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susceptibility to symptomatic and placental malaria caused by P. falciparum [24,27]. Interest-
ingly, this SNP has been shown to correlate with high Plasmodium parasitemia and low pro-
duction of IFN-γ and TNF-α [24,68,69]. We show the genotype C/C of the SNP TLR9 -1237C/
T was associated with high parasite load. Together, these data confirm recent studies with Pf-
malaria and suggest that TLR9 may play a key role in controlling parasitemia [24,69]. TLR9-
depleted mice showed loss in control of parasitic infections compared to wild type mice
[23,70]. SNPs in TLR9 appear to predispose Indian individuals to severe malaria [71] and these
findings were confirmed in a meta-analysis study with 665 severe malaria patients and 1,187
uncomplicated malaria individuals from India and Africa, with an association of variants
-1486C/T and -1237C/T of TLR9 with severe malaria [72].
This study has some limitations. Although the levels of associations with Pv-malaria and
parasitemia are high, the study population is small. It needs validation with a larger sample
size to confirm the importance of TLR9 and TLR5 in Pv-malaria. The small sample size does
not allow intra-comparison of the genotypes and alleles studied with clinical manifestations of
Pv-malaria, including in asymptomatic, mild, and severe malaria.
To our knowledge, this is the first study to show that variants in the TLR pathway may be
involved in the pathogenesis of P. vivax malaria. TLRs are key mediators in response to malaria
as they trigger the expression of proinflammatory cytokines to inhibit parasite growth. TLR5
R392StopCodon and TLR9 -1486C/Tmay predispose individuals to P. vivax malaria, while
TLR9 -1237C/Twas associated with Pv-malaria with high parasitemia. However, additional
studies should be conducted in other endemic areas to confirm the role of host genetics in
infection and pathogenesis of Pv-malaria.
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